Skip to main content
Journal cover image

Utility of a risk assessment model in predicting 30 day unplanned hospital readmission in adult patients receiving outpatient parenteral antimicrobial therapy.

Publication ,  Journal Article
Brenneman, E; Funaro, J; Dicks, K; Yarrington, M; Lee, H-J; Erkanli, A; Hung, F; Drew, R
Published in: JAC Antimicrob Resist
February 2023

OBJECTIVES: Outpatient parenteral antimicrobial therapy (OPAT) is associated with high hospital readmission rates. A 30 day unplanned readmission risk prediction model for OPAT patients has been developed in the UK. Given significant differences in patient mix and methods of OPAT delivery, we explored the model for its utility in Duke University Health System (DUHS) patients receiving OPAT. METHODS: We analysed OPAT episodes of adult patients from two hospitals between 1 July 2019 and 1 February 2020. The discriminative ability of the model to predict 30 day unplanned all-cause and OPAT-related admission was examined. An updated model was created by logistic regression with the UK risk factors and additional risk factors, OPAT delivery in a skilled nursing facility, vancomycin use and IV drug abuse. RESULTS: Compared with patients of the UK cohort, our study patients were of higher acuity, treated for more invasive infections, and received OPAT through different modes. The 30 day unplanned readmission rate in our cohort was 20% (94/470), with 59.5% (56/94) of those being OPAT-related. The original model was unable to discriminate for all-cause readmission with a C-statistic of 0.52 (95% CI 0.46-0.59) and for OPAT-related readmission with a C-statistic of 0.55 (95% CI 0.47-0.64). The updated model with additional risk factors did not have improved performance, with a C-statistic of 0.55 (95% CI 0.49-0.62). CONCLUSIONS: The UK 30 day unplanned hospital readmission model performed poorly in predicting readmission for the OPAT population at a US academic medical centre.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JAC Antimicrob Resist

DOI

EISSN

2632-1823

Publication Date

February 2023

Volume

5

Issue

1

Start / End Page

dlad019

Location

England

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences
  • 3207 Medical microbiology
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Brenneman, E., Funaro, J., Dicks, K., Yarrington, M., Lee, H.-J., Erkanli, A., … Drew, R. (2023). Utility of a risk assessment model in predicting 30 day unplanned hospital readmission in adult patients receiving outpatient parenteral antimicrobial therapy. JAC Antimicrob Resist, 5(1), dlad019. https://doi.org/10.1093/jacamr/dlad019
Brenneman, Ethan, Jason Funaro, Kristen Dicks, Michael Yarrington, Hui-Jie Lee, Alaattin Erkanli, Frances Hung, and Richard Drew. “Utility of a risk assessment model in predicting 30 day unplanned hospital readmission in adult patients receiving outpatient parenteral antimicrobial therapy.JAC Antimicrob Resist 5, no. 1 (February 2023): dlad019. https://doi.org/10.1093/jacamr/dlad019.
Brenneman E, Funaro J, Dicks K, Yarrington M, Lee H-J, Erkanli A, et al. Utility of a risk assessment model in predicting 30 day unplanned hospital readmission in adult patients receiving outpatient parenteral antimicrobial therapy. JAC Antimicrob Resist. 2023 Feb;5(1):dlad019.
Brenneman, Ethan, et al. “Utility of a risk assessment model in predicting 30 day unplanned hospital readmission in adult patients receiving outpatient parenteral antimicrobial therapy.JAC Antimicrob Resist, vol. 5, no. 1, Feb. 2023, p. dlad019. Pubmed, doi:10.1093/jacamr/dlad019.
Brenneman E, Funaro J, Dicks K, Yarrington M, Lee H-J, Erkanli A, Hung F, Drew R. Utility of a risk assessment model in predicting 30 day unplanned hospital readmission in adult patients receiving outpatient parenteral antimicrobial therapy. JAC Antimicrob Resist. 2023 Feb;5(1):dlad019.
Journal cover image

Published In

JAC Antimicrob Resist

DOI

EISSN

2632-1823

Publication Date

February 2023

Volume

5

Issue

1

Start / End Page

dlad019

Location

England

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences
  • 3207 Medical microbiology
  • 3202 Clinical sciences